The global chronic inflammatory demyelinating polyneuropathy (CIDP) market size was $1,852.4 million in 2022 and is expected to reach at $4,083.2 million by 2033 with a CAGR of 7.45% during the ...

Treatment options for chronic inflammatory demyelinating polyneuropathy include intravenous immunoglobulin, corticosteroids, plasmapheresis (plasma exchange), and a newer medication called Vyvgart ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnosis involves a neurological exam, nerve conduction studies, electromyography, cerebrospinal fluid analysis, nerve biopsy, and, in ...

Vyvgart Hytrulo is FDA-approved for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). It is given once a week as a shot under the skin.

Chronic inflammatory demyelinating polyneuropathy diagnosis involves a neurological exam, nerve conduction studies, and electromyography, among other tests and tools. Healthline Health Conditions ...

DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic ...

Treatment for chronic inflammatory demyelinating polyneuropathy can include intravenous immunoglobulin, corticosteroids, plasmapheresis, and Vyvgart Hytrulo. Healthline Health Conditions ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a long-term neurological disorder that targets your body’s nerves. Anyone can get CIDP, but it’s most common in older adults and ...

Netherlands-based argenx has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended its efgartigimod alfa treatment, brand name ...